↓ Skip to main content

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Overview of attention for article published in BMC Cancer, April 2014
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (58th percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
129 Dimensions

Readers on

mendeley
89 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Published in
BMC Cancer, April 2014
DOI 10.1186/1471-2407-14-258
Pubmed ID
Authors

Giles W Robinson, Brent A Orr, Amar Gajjar

Abstract

Standard therapies for high grade glioma have failed to substantially improve survival and are associated with significant morbidity. At relapse, high grade gliomas, such as glioblastoma multiforme, are refractory to therapy and universally fatal. BRAF V600E-mutations have been described in a modest 6% to 7% of primary central nervous system (CNS) tumors, but with increased prevalence in the pediatric population and in certain brain tumor subtypes. The use of BRAF inhibitors have transformed melanoma therapy however their use in brain tumors remains unproven.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 1%
Spain 1 1%
United States 1 1%
Philippines 1 1%
Unknown 85 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 15 17%
Researcher 15 17%
Student > Postgraduate 11 12%
Student > Bachelor 10 11%
Other 10 11%
Other 21 24%
Unknown 7 8%
Readers by discipline Count As %
Medicine and Dentistry 45 51%
Agricultural and Biological Sciences 12 13%
Biochemistry, Genetics and Molecular Biology 8 9%
Neuroscience 5 6%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Other 5 6%
Unknown 10 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2016.
All research outputs
#2,968,550
of 6,912,770 outputs
Outputs from BMC Cancer
#1,008
of 3,146 outputs
Outputs of similar age
#65,612
of 171,615 outputs
Outputs of similar age from BMC Cancer
#43
of 128 outputs
Altmetric has tracked 6,912,770 research outputs across all sources so far. This one has received more attention than most of these and is in the 54th percentile.
So far Altmetric has tracked 3,146 research outputs from this source. They receive a mean Attention Score of 3.3. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 171,615 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.
We're also able to compare this research output to 128 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.